collection
MENU ▼
Read by QxMD icon Read
search

Cholesterol

shared collection
17 papers 0 to 25 followers Interested in managing lipid disorders? Check it out-
By Michael Kelly Assistant Professor
https://www.readbyqxmd.com/read/28514624/evacetrapib-and-cardiovascular-outcomes-in-high-risk-vascular-disease
#1
RANDOMIZED CONTROLLED TRIAL
A Michael Lincoff, Stephen J Nicholls, Jeffrey S Riesmeyer, Philip J Barter, H Bryan Brewer, Keith A A Fox, C Michael Gibson, Christopher Granger, Venu Menon, Gilles Montalescot, Daniel Rader, Alan R Tall, Ellen McErlean, Kathy Wolski, Giacomo Ruotolo, Burkhard Vangerow, Govinda Weerakkody, Shaun G Goodman, Diego Conde, Darren K McGuire, Jose C Nicolau, Jose L Leiva-Pons, Yves Pesant, Weimin Li, David Kandath, Simon Kouz, Naeem Tahirkheli, Denise Mason, Steven E Nissen
BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease...
May 18, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28465133/jcl-roundtable-future-of-the-lipid-laboratory-choosing-valuable-measures-among-the-lipoproteins-part-1
#2
REVIEW
William Virgil Brown, Yehuda Handelsman, Seth S Martin, Pamela B Morris
The measurement of cholesterol and triglycerides as indicators of metabolic disorders and most particularly of vascular disease risk has been of growing importance to physicians and epidemiologists over the past century. This was refocused on the lipoproteins, the specific packages in blood that carry these lipids, by John Gofman, MD, PhD, and Don Fredrickson, MD, more than 50 years ago. We continue to learn about the metabolism of these large molecular structures and their relationship to arteriosclerosis as new genetic and interventional studies are published...
April 21, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28156151/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease-executive-summarycomplete-appendix-to-guidelines-available-at-http-journals-aace-com
#3
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson, Farhad Zangeneh, Michael A Bush
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Each Recommendation is based on a diligent review of the clinical evidence with transparent incorporation of subjective factors. RESULTS: The Executive Summary of this document contains 87 Recommendations of which 45 are Grade A (51...
April 2, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/27798247/rechallenging-statin-therapy-in-veterans-with-statin-induced-myopathy-post-vitamin-d-replenishment
#4
Jenny H Kang, Quynh-Nhu Nguyen, Juleann Mutka, Quang A Le
BACKGROUND: Statins are the primary class of medications used to lower cholesterol and reduce risks for coronary heart disease. However, statin muscular adverse effects are one of the main reasons for statin nonadherence and a barrier to cardiovascular risk reduction. OBJECTIVES: The primary objective of our study was to examine the effect of replenishing vitamin D on statin-induced myopathy in veteran patients who failed to maintain statin therapy in a pharmacist-run ambulatory care setting...
October 24, 2016: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/27888640/chronotherapy-versus-conventional-statins-therapy-for-the-treatment-of-hyperlipidaemia
#5
REVIEW
Jose Manuel Izquierdo-Palomares, Jesus Maria Fernandez-Tabera, Maria N Plana, Almudena Añino Alba, Pablo Gómez Álvarez, Inmaculada Fernandez-Esteban, Luis Carlos Saiz, Pilar Martin-Carrillo, Óscar Pinar López
BACKGROUND: Elevated levels of total cholesterol and low-density lipoprotein play an important role in the development of atheromas and, therefore, in cardiovascular diseases. Cholesterol biosynthesis follows a circadian rhythm and is principally produced at night (between 12:00 am and 6:00 am). The adjustment of hypolipaemic therapy to biologic rhythms is known as chronotherapy. Chronotherapy is based on the idea that medication can have different effects depending on the hour at which it is taken...
November 26, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27678434/lifestyle-intervention-enhances-high-density-lipoprotein-function-among-patients-with-metabolic-syndrome-only-at-normal-low-density-lipoprotein-cholesterol-plasma-levels
#6
Boris Hansel, Dominique Bonnefont-Rousselot, Alexina Orsoni, Randa Bittar, Philippe Giral, Ronan Roussel, Michel Marre, Kamel Mohammedi, Eric Bruckert, Martin John Chapman, Anatol Kontush
BACKGROUND: Metabolic syndrome (MetS) is associated with altered lipoprotein metabolism and impairment in the functionality of small, dense high-density lipoprotein (HDL) particles secondary to compositional alterations. OBJECTIVE: The objective of this study was to investigate the capacity of a lifestyle program to improve the composition and antioxidative function (AOX) of small dense HDL3c in MetS. METHODS: Patients with MetS (n = 33) not taking lipid-lowering drugs were recruited to follow a 12-week educational program to reduce caloric intake and to increase physical activity...
September 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27678439/efficacy-and-safety-of-gemcabene-as-add-on-to-stable-statin-therapy-in-hypercholesterolemic-patients
#7
Evan Stein, Harold Bays, Michael Koren, Rebecca Bakker-Arkema, Charles Bisgaier
BACKGROUND: Ezetimibe added to statin therapy further reduces LDL-C and clinical atherosclerotic cardiovascular disease compared to statin alone. However, the number of effective and safe oral agents for patients not at LDL-C goal is limited. In prior clinical trials, gemcabene reduced LDL-C and was generally well-tolerated in nearly 900 patients treated for up to 12 weeks. OBJECTIVE: To evaluate the LDL-C lowering and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients...
September 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27567407/2016-esc-eas-guidelines-for-the-management-of-dyslipidaemias
#8
Alberico L Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M John Chapman, Heinz Drexel, Arno W Hoes, Catriona S Jennings, Ulf Landmesser, Terje R Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W M Monique Verschuren, Charalambos Vlachopoulos, David A Wood, Jose Luis Zamorano
No abstract text is available yet for this article.
October 14, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27040132/cholesterol-lowering-in-intermediate-risk-persons-without-cardiovascular-disease
#9
RANDOMIZED CONTROLLED TRIAL
Salim Yusuf, Jackie Bosch, Gilles Dagenais, Jun Zhu, Denis Xavier, Lisheng Liu, Prem Pais, Patricio López-Jaramillo, Lawrence A Leiter, Antonio Dans, Alvaro Avezum, Leopoldo S Piegas, Alexander Parkhomenko, Katalin Keltai, Matyas Keltai, Karen Sliwa, Ron J G Peters, Claes Held, Irina Chazova, Khalid Yusoff, Basil S Lewis, Petr Jansky, Kamlesh Khunti, William D Toff, Christopher M Reid, John Varigos, Gregorio Sanchez-Vallejo, Robert McKelvie, Janice Pogue, Hyejung Jung, Peggy Gao, Rafael Diaz, Eva Lonn
BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo...
May 26, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27206952/icosapent-ethyl-eicosapentaenoic-acid-ethyl-ester-effects-on-plasma-apolipoprotein-c-iii-levels-in-patients-from-the-marine-and-anchor-studies
#10
Christie M Ballantyne, Harold E Bays, Rene A Braeckman, Sephy Philip, William G Stirtan, Ralph T Doyle, Paresh N Soni, Rebecca A Juliano
BACKGROUND: Apolipoprotein C-III (ApoC-III) regulates lipoprotein and triglyceride (TG) metabolism and may have a causal role in cardiovascular disease. In the Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension (MARINE) and ANCHOR studies, icosapent ethyl, a high-purity prescription eicosapentaenoic acid ethyl ester, reduced TG, and other atherogenic lipid parameters without increasing low-density lipoprotein cholesterol (LDL-C) compared with placebo...
May 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27242350/effects-of-rosuvastatin-versus-atorvastatin-alone-or-in-combination-on-lipoprotein-a
#11
Marija Vavlukis, Kristina Mladenovska, Arlinda Daka, Aleksandar Dimovski, Saska Domazetovska, Sonja Kuzmanovska, Sasko Kedev
BACKGROUND: There are little evidences about the therapeutic efficacy of different lipid-lowering agents in the reduction of elevated lipoprotein(a) [Lp(a)]. OBJECTIVE: testing the effect of different lipid-lowering agents on elevated Lp(a). METHODS: prospective interventional study performed in patients with CAD, or high CAD risk, with Lp(a), >50 mg/dL. Lp(a), total cholesterol (C), HDL-C, LDL-C, triglycerides (TGs), apolipoprotein (Apo) A1, Apo B, enzymes of myocyte and hepatic injury were comparatively analyzed between 4 lipid-lowering strategies: rosuvastatin (R group) 40 mg, atorvastatin (A group) 80 mg, atorvastatin 40 mg add-on micronized fenofibrate (A+F group), and atorvastatin 40 mg add-on 1 g extended-release niacin (A+ERN group)...
August 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/26699442/national-lipid-association-recommendations-for-patient-centered-management-of-dyslipidemia-part-2
#12
Terry A Jacobson, Kevin C Maki, Carl E Orringer, Peter H Jones, Penny Kris-Etherton, Geeta Sikand, Ralph La Forge, Stephen R Daniels, Don P Wilson, Pamela B Morris, Robert A Wild, Scott M Grundy, Martha Daviglus, Keith C Ferdinand, Krishnaswami Vijayaraghavan, Prakash C Deedwania, Judith A Aberg, Katherine P Liao, James M McKenney, Joyce L Ross, Lynne T Braun, Matthew K Ito, Harold E Bays, W Virgil Brown, James A Underberg
An Expert Panel convened by the National Lipid Association previously developed a consensus set of recommendations for the patient-centered management of dyslipidemia in clinical medicine (part 1). These were guided by the principle that reducing elevated levels of atherogenic cholesterol (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) reduces the risk for atherosclerotic cardiovascular disease. This document represents a continuation of the National Lipid Association recommendations developed by a diverse panel of experts who examined the evidence base and provided recommendations regarding the following topics: (1) lifestyle therapies; (2) groups with special considerations, including children and adolescents, women, older patients, certain ethnic and racial groups, patients infected with human immunodeficiency virus, patients with rheumatoid arthritis, and patients with residual risk despite statin and lifestyle therapies; and (3) strategies to improve patient outcomes by increasing adherence and using team-based collaborative care...
November 2015: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27206934/a-review-of-low-density-lipoprotein-cholesterol-treatment-strategies-and-its-impact-on-cardiovascular-disease-morbidity-and-mortality
#13
REVIEW
Rishi K Wadhera, Dylan L Steen, Irfan Khan, Robert P Giugliano, JoAnne M Foody
Cardiovascular (CV) disease is a leading cause of death worldwide, accounting for approximately 31.4% of deaths globally in 2012. It is estimated that, from 1980 to 2000, reduction in total cholesterol accounted for a 33% decrease in coronary heart disease (CHD) deaths in the United States. In other developed countries, similar decreases in CHD deaths (ranging from 19%-46%) have been attributed to reduction in total cholesterol. Low-density lipoprotein cholesterol (LDL-C) has now largely replaced total cholesterol as a risk marker and the primary treatment target for hyperlipidemia...
May 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/27206943/treatment-with-etc-1002-alone-and-in-combination-with-ezetimibe-lowers-ldl-cholesterol-in-hypercholesterolemic-patients-with-or-without-statin-intolerance
#14
Paul D Thompson, Diane E MacDougall, Roger S Newton, Janice R Margulies, Jeffrey C Hanselman, David G Orloff, James M McKenney, Christie M Ballantyne
BACKGROUND: ETC-1002 is an oral, once-daily, first-in-class medication being developed to treat hypercholesterolemia. OBJECTIVES: To compare 2 doses of ETC-1002, alone or combined with ezetimibe 10 mg (EZE), vs EZE monotherapy for lowering low-density lipoprotein cholesterol (LDL-C). METHODS: This phase 2b, multicenter, double-blind trial-evaluated hypercholesterolemic patients (LDL-C, 130 to 220 mg/dL) with (n = 177) or without (n = 171) muscle-related intolerance to ≥2 statins; 1 at lowest approved dose...
May 2016: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/25468918/dyslipidaemia-what-s-around-the-corner
#15
Anthony S Wierzbicki, Dilinika Perera, Mfon Ewang-Emukowhate
Hyperlipidaemia is a major risk factor for the development of atherosclerosis and cardiovascular disease. Statins are the mainstay of therapy and new guidelines focus on the use of these agents without specific targets for low-density lipoprotein (LDL)-cholesterol or non high-density lipoprotein (HDL)-cholesterol. However, patients remain at risk of cardiovascular disease despite statin therapy so new drugs are required. This article reviews therapies in development to further lower LDL-cholesterol (Proprotein convertase subtilisin/kexin-9 (PCSK-9) inhibitors), raise HDL-holesterol (cholesterol ester transfer protein inhibitors (CETPIs)) and reduce triglycerides (novel peroxisome proliferator-activated receptor (PPAR)-agonists and omega-3 fatty acid preparations)...
December 2014: Clinical Medicine: Journal of the Royal College of Physicians of London
https://www.readbyqxmd.com/read/26687339/effects-of-combination-of-ezetimibe-and-rosuvastatin-on-coronary-artery-plaque-in-patients-with-coronary-heart-disease
#16
RANDOMIZED CONTROLLED TRIAL
Xiaofang Wang, Xiaoyan Zhao, Ling Li, Haimu Yao, Yan Jiang, Jinying Zhang
BACKGROUND: In approximately 80% of cardiovascular disease-related deaths, patients suffer from coronary atherosclerotic heart disease. Ezetimibe is the first intestinal cholesterol absorption inhibitor. Its combination with statins for treating coronary atherosclerotic heart disease has attracted attention worldwide. METHODS: The study group comprised 106 patients with coronary atherosclerotic heart disease and hyperlipidaemia. Each was randomly assigned to one of two groups: (1) Ezetimibe (10mg, once a night) plus rosuvastatin (10mg, once a night) (n=55) or (2) Rosuvastatin alone (10mg, once a night) (n=51)...
May 2016: Heart, Lung & Circulation
https://www.readbyqxmd.com/read/26864092/long-term-safety-and-efficacy-of-lowering-low-density-lipoprotein-cholesterol-with-statin-therapy-20-year-follow-up-of-west-of-scotland-coronary-prevention-study
#17
COMPARATIVE STUDY
Ian Ford, Heather Murray, Colin McCowan, Chris J Packard
BACKGROUND: Extended follow-up of statin-based low-density lipoprotein cholesterol lowering trials improves the understanding of statin safety and efficacy. Examining cumulative cardiovascular events (total burden of disease) gives a better appreciation of the clinical value of statins. This article evaluates the long-term impact of therapy on mortality and cumulative morbidity in a high-risk cohort of men. METHODS AND RESULTS: The West of Scotland Coronary Prevention Study was a primary prevention trial in 45- to 64-year-old men with high low-density lipoprotein cholesterol...
March 15, 2016: Circulation
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"